Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2007-05-01
2007-05-01
Brumback, Brenda (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S239100, C424S247100
Reexamination Certificate
active
09393590
ABSTRACT:
The invention includes liquid formulations of botulinum toxin that are stable to storage in liquid form at standard refrigerator temperatures for at least 1–2 years and to storage at higher temperatures for at least 6 months. The invention also includes methods of treatment using such formulations for various therapeutic and cosmetic purposes.
REFERENCES:
patent: 4932936 (1990-06-01), Dykstra et al.
patent: 5053005 (1991-10-01), Borodic et al.
patent: 5183462 (1993-02-01), Borodic
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5512547 (1996-04-01), Johnson et al.
patent: 5562899 (1996-10-01), Gerber
patent: 5696077 (1997-12-01), Johnson et al.
patent: 5714468 (1998-02-01), Binder
patent: 5721215 (1998-02-01), Aoki et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6146902 (2000-11-01), McMaster
patent: 6350455 (2002-02-01), Donovan
patent: 6358513 (2002-03-01), Voet et al.
patent: 0 593 176 (1994-04-01), None
patent: WO 93/05800 (1993-04-01), None
patent: WO 95/17904 (1993-07-01), None
patent: WO 94/00481 (1994-01-01), None
patent: WO 94/28922 (1994-12-01), None
patent: WO 94/28923 (1994-12-01), None
patent: WO 95/05842 (1995-03-01), None
patent: WO 95/17904 (1995-07-01), None
patent: WO 95/28171 (1995-10-01), None
patent: WO 95/30431 (1995-11-01), None
patent: WO 95/03041 (1996-02-01), None
patent: WO 96/11699 (1996-04-01), None
patent: WO 96/39167 (1996-12-01), None
patent: WO 97/35604 (1997-10-01), None
Schwarz W. Archiv. fur lebensmittelhygiene 30: 1-40, pp. 29-33, 1979 (original & translated material).
Schantz and Johnson. In: Therapy with Botulinum Toxin. (Ed) J. Jankovic et al. Marcel Dekker, Inc. New York, 41-49, 1994.
Grethlein et al. Pain Med. 2: #203, p. 239, 2001.
Saprykina et al. Zh. Mikrobiol. Epidermol. Immunobiol. 9: 86-91, 1980.
Webster's II Riverside University Dictionary, The Riverside Publishing Company, p. 1032, 1984.
Schantz and Sugiyama. J. Agr. Food Chem. 22: 26-30, 1974.
Gimenez et al. Appl. Environ. Microbiol. 53: 2827-2830, 1987.
Sloop et al. Neurology 48: 249-253, 1997.
Schantz et al. Perspect. Biol. Med. 40 (3) Spring, 317-327, 1997.
Moyer et al. In: Therapy with Botulinum Toxin. (Ed) J. Jankovic et al. Marcel Dekker, Inc. New York, pp. 71-85, 1994.
Uvarova et al. Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii 11: 42-46, 1980—English abstract.
McLellan et al., Therapeutic botulinum type A toxin: factors affecting potency, Toxicon, 1996, vol. 34, No. 9, pp. 975-985. See IDS filed Apr. 25, 2006, p. 3 of 4.
Gartlan et al., Crystalline preparation of botulinum toxin type A (Botox): degradation in potency with storage, Otolaryngol Head Neck Surg. Nov. 1993, vol. 108, No. 2, pp. 135-140. See IDS filed Apr. 25, 2006, p. 3 of 4.
Goodnough et al. Stabilization of Botulinum Toxin Type A during Lyophilization, Applied and Environmental Microbiology, Oct. 1992, 3426-3428. See IDS filed Apr. 25, 2006, p. 4 of 4.
First, E.R., et al., “Dose Standardisation of Botulinum Toxin,” The Lancet, vol. 343. p. 1035, ( Apr. 23, 1994).
Gartlan, M.G., et al., “Crystalline preparation of botulinum toxin type A (Botox): Degradation in potency with storage,” Otolaryngology, vol. 108, p. 135-140, (1993).
Hambleton, B.C., et al., “Production, Purification and Toxoiding ofClostridium botulinumType A Toxin,” Biomedical Aspects of Botulism, Academic Press (US), p. 247-260, (1981).
Kadis, S., et al., “Microbial Toxins,” Bacterial Protein Toxins, Academic Press (US), p. 1-68, (1971).
Lamanna, C., et al., “The Isolation of Type B Botulinum Toxin,” Journal of Bacteriology, (US), vol. 54, p. 575-584, (1947).
Melling, J., et al., “Clostridium botulinumToxins: Nature and Preparation for Clinical Use,” Eye, vol. 2, p. 16-23, (1988).
Schantz, E.J., et al., “Microbiological Methods,” Journal of the AOAC (UK), Association of Official Analytical Chemists, vol. 61 ( No. 1), p. 96-99, (1978).
Schantz, E.J., et al., “Quality of Botulinum Toxin For Human Treatment,” Botulinum and Tetanus Neurotoxins, B.R. Dasgupta, ed., Plenum Press, p. 657-659, (1993).
Sloop, R.R., MD, et al., “Human response to botulinum toxin injection: Type B compared with type A,”, The American Academy of Neurology (US), vol. 49, p. 189-194, ( Jul. 27, 1997).
Sugii, S., et al., “Correlation Between Oral Toxicity and In Vitro Stability ofClostridium botulinumType A and B Toxins of Different Molecular Sizes,” Infection and Immunity, American Society of Microbiology (US), vol. 16, p. 910-914, (1977).
Wright, G.P., “The Neurotoxins ofClostridium botulinumandClostridium tetani,” Pharmacology, vol. 7, p. 413-465, (1955).
Schantz, E.J., et al., “Dose standardisation of botulinum toxin,” The Lancet, vol. 335, p. 421, ( 1994).
Tsui, J.K.C., et al., “Botulinum toxin type B in the treatment of cervical dystonia: A pilot study,” Neurology, vol. 45, p. 2109-2110, (1995).
Moyer, E.D. et al., “Effects of Intramuscular Injection of Botulinum Toxin Type B in Nonhuman Primates,” Botulinum and Tetanus Neurotoxins, Plenum Press (US), p. 655-656, (1993).
Lew, M.F. et al., “Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia” Neurology (US), vol. 49, p. 701-707, (1997).
Prevot, A.R. et al., “New Studies of Botulism and its Five Toxin Types,” Annals of the Pasteur Institute (FR), vol. 85, p. 2-20, (1953).
Simpson, Lance L. “Botulinum Toxin: A Deadly Poison Sheds Its Negative Image”Annals of Internal Medicine, 125:616-617, Oct. 1, 1996.
Henry S. Sacks et al,Clostridium botulinumType E Toxin: Effect of pH and Method of Purification on Molecular Weight, Applied Microbiology, Sep. 1974, p. 374-382, vol. 28:3, American Society for Microbiology, USA.
Iwao Ohishi et al, Purification ofClostridium botulinumType F Progenitor Toxin, Applied Microbiology, Dec. 1974, p. 923-928, vol. 28:6, American Society for Microbiology, USA.
Iwao Ohishi et al, Molecular Construction ofClostridium botulinumType F Progenitor Toxin, Applied Microbiology, Apr. 1975, p. 444-447, vol. 29:4, American Society for Microbiology, USA.
Shunji Sugii et, Correlation Between Oral Toxicity and In Vitro Stability ofClostridium botulinumType A and B Toxins of Different Molecular Sizes, Infection and Immunity, Jun. 1977, p. 910-914, vol. 16:3, American Society for Microbiology, USA.
Iwao Ohishi et al, Activation of Botulinum Toxins in the Absence of Nicking, Infection and Immunity, Aug. 1977, p. 402-407, vol. 17:2, American Society for Microbiology, USA.
Albert L. Lehiniger, The Molecular Basis of Cell Structure and Function, Biochemistry (Second Edition), Jul. 1978, 45-50, Worth Publishers, Inc., New York, USA.
Iwao Ohishi et al, Oral Toxicities ofClostridium botulinumType C and D Toxins of Different Molecular Sizes, Infection and Immunity, May 1980, p. 303-309; vol. 28:2.
Iwao Ohishi et al, Purification and Characterization of Two Components of Botulinum C2Toxin, Infection and Immunity, Dec. 1980, p. 668-673, vol. 30:3.
Leon Lachman, Ph.D. et al, The Theory and Practice of Industrial Pharmacy, third edition, 1986, p. 458-460, Lea & Febiger, Philadelphia, USA.
Flora Chen et al, Biophysical Characterization of the Stability of the 150-Kilodalton Botulinum Toxin, the Nontoxic Component, and the 900-Kilodalton Botulinum Toxin Complex Species, Infection and Immunity, Jun. 1988, p. 2420-2425, vol. 66:6, American Society of Microbiology, USA.
J. Melling et al.,Clostridium botulinumToxins: Nature and Preparation for Clinical Use; Eye, 1988:2, p. 16-23.
J. Halouzka et al, Effect of pH on the Stability of Type-C Toxin ofClostridium botulinum, Folia Microbiol, 1992, p. 157-158, vol. 37:2.
Giampietro Schiavo et al, Botulinum G Neurotoxin Cleaves VAMP/Synaptobrevin at a Single Ala-Ala Peptide Bond, The Journal of Biological Chemistry, Aug. 12, 1994, p. 20213-20216, vol. 269:32, The American
Hirtzer Pamela
Moyer Elizabeth
Brumback Brenda
Halluin Albert P.
Hunt Sharon
Nguyen Lien-Chi
Solstice Neurosciences, Inc.
LandOfFree
Stable liquid formulations of botulinum toxin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stable liquid formulations of botulinum toxin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable liquid formulations of botulinum toxin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3751728